Target intelligence / Profile preview

Other uronic acid-containing polysaccharides

Molecular classification
Polysaccharide, Carbohydrate, Glycan, Macromolecule
01

Overview

Other uronic acid-containing polysaccharides represent a diverse group of acidic glycans, including bacterial alginates and plant-derived pectins, characterized by the presence of hexuronic acid residues. In clinical medicine, these polysaccharides are critical components of the pathological mucus and biofilms found in the lungs of patients with cystic fibrosis and other chronic respiratory conditions. They provide structural stability to the extracellular matrix by cross-linking with divalent cations like calcium, creating a barrier that impedes drug delivery and immune cell penetration. Therapeutic strategies targeting these molecules, such as the use of alginate oligosaccharides (e.g., OligoG), aim to modulate the rheological properties of mucus and disrupt biofilm architecture. By interfering with the polymer-polymer interactions, these therapies enhance the clearance of secretions and potentiate the activity of antimicrobial agents against persistent infections.

Other names
Acidic polysaccharidesPolyanionic polysaccharidesUronansHexuronic acid-containing polysaccharidesUronic acid-containing exopolysaccharides
02

Mechanism of action

Disruption of the extracellular polymeric network through competitive binding and chelation of divalent cations (e.g., Ca2+), leading to reduced mucus viscosity and biofilm fragmentation.

03

Biological functions

Structural supportBiofilm matrix formationMucus rheology regulationIon binding and chelationCell adhesion
04

Disease associations

Cystic fibrosisBacterial infectionChronic obstructive pulmonary disease (COPD)InflammationBiofilm-associated infections
05

Safety considerations

Potential off-target effects on host glycosaminoglycansImmunogenicity of non-human derived enzymesChallenges in drug delivery to deep lung tissuesTransient airway irritation upon inhalation
06

Interacting drugs

OligoG (OligoG CF-5/20)

2 more in the full profile.

07

Biomarkers

Sputum viscosityBiofilm densityUronic acid concentration in sputumForced expiratory volume (FEV1)

Beyond the preview

Go deeper on Other uronic acid-containing polysaccharides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other uronic acid-containing polysaccharides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call